双極性障害または統合失調症患者の代謝および精神医学的健康に対するケトジェニックダイエットの影響
双極性障害または統合失調症患者の肥満、代謝異常、および精神症状に対する低炭水化物、高脂肪、ケトジェニックダイエットの影響:パイロット試験
To initiate a low-carbohydrate, high-fat (LCHF) or ketogenic dietary (KD) intervention among a cohort of outpatients with either schizophrenia or bipolar illness who also have metabolic abnormalities, overweight/obesity, and/or are currently taking psychotropic medications experiencing metabolic side effects.
調査の概要
状態
介入・治療
詳細な説明
Adults with mental illness represent a high-risk, marginalized group in the current metabolic and obesity epidemic. Among US adults with severe mental illness, metabolic syndrome are highly prevalent conditions having severe consequences, with patients estimated to die on average 25 years earlier than the general population largely of premature cardiovascular disease. Many psychiatric medications, particularly neuroleptics and mood stabilizers, may, in addition, contribute to metabolic side effects and weight gain. Low-carbohydrate high-fat (LCHF) or ketogenic diets (KD) have been shown to reduce cardiovascular risk in those with insulin resistance. Recent findings support the idea that bipolar disorder, along with other psychiatric diseases schizophrenia, may have roots of metabolic dysfunction: cerebral glucose hypometabolism, oxidative stress, as well as mitochondrial and neurotransmitter dysfunction which has downstream effects on synapse connections. A KD diet provides alternative fuel to the brain aside from glucose and is believed to contain beneficial neuroprotective effects, including stabilization of brain networks, reduction of inflammation and oxidative stress. The purpose of this study is to evaluate both the metabolic and psychiatric outcomes with a KD diet in this psychiatric population.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
California
-
Stanford、California、アメリカ、94305
- Stanford University Department of Psychiatry & Behavioral Sciences
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18-75 years old
- Meet DSM V criteria for schizophrenia or bipolar disorder, any subtype, for > 1 year and clinically stable (with no hospitalization for past 3 months)
- Currently taking psychotropic medication and gained at least 5% weight since starting medication or have a BMI greater than or equal to 26 kg/m2 or presence of at least one metabolic abnormality (hypertriglyceridemia, insulin resistance, dyslipidemia, impaired glucose tolerance)
- Willing to consent to all study procedures and attend follow-up appointments and motivated to follow the dietary program.
- Sufficient control over their food intake to adhere to study diets.
- Willingness to regularly monitor blood pressure, glucose, dietary intake, and body weight over the 4-month trial
Exclusion Criteria:
-
Any subject pregnant or nursing
-
Comorbidity of developmental delay
-
Active substance abuse with illicit drugs or alcohol
-
In a current severe mood or psychotic state when entering the study that would prohibit compliance with study visits or dietary program.
-
Anyone who has been hospitalized or taken clozapine over the past 3 months
-
Inability to complete baseline measurements
-
Severe renal or hepatic insufficiency
-
Cardiovascular dysfunction, including diagnosis of:
- Congestive heart failure
- Angina
- Arrhythmias
- Cardiomyopathy
- Valvular heart disease
-
Any other medical condition that may make either diet dangerous as determined by the study medical team (e.g. anorexia nervosa)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Ketogenic Diet 16 Week Group
Patients follow ketogenic diet for 16 weeks, with monitoring of physical and psychological health and coaching support |
Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in heart rate from baseline
時間枠:Baseline, 16 weeks
|
Heart rate recorded at 9 visits during study |
Baseline, 16 weeks
|
|
Change in blood pressure from baseline
時間枠:Baseline, 16 weeks
|
Blood pressure recorded at 9 visits during study |
Baseline, 16 weeks
|
|
Change in weight from baseline
時間枠:Baseline, 16 weeks
|
Weight recorded at 9 visits during study |
Baseline, 16 weeks
|
|
Change in waist circumference from baseline
時間枠:Baseline, 16 weeks
|
waist circumference measured at 9 visits during study |
Baseline, 16 weeks
|
|
Change in visceral fat mass from baseline
時間枠:Baseline, 16 weeks
|
Body composition (SECA) recorded at 5 visits during study |
Baseline, 16 weeks
|
|
Change in body fat mass from baseline
時間枠:Baseline, 16 weeks
|
Body composition (SECA) recorded at 5 visits during study |
Baseline, 16 weeks
|
|
Percent Change in Hemoglobin A1c from baseline
時間枠:Baseline, 16 weeks
|
Hemoglobin A1c recorded at initial and final visits |
Baseline, 16 weeks
|
|
Change in insulin resistance measure (HOMA-IR) from baseline
時間枠:Baseline, 16 weeks
|
HOMA-IR measured at initial and final visits |
Baseline, 16 weeks
|
|
Change in inflammatory marker (hsCRP) from baseline
時間枠:Baseline, 16 weeks
|
hsCRP measured at initial and final visits |
Baseline, 16 weeks
|
|
Change in lipid profile TG (triglycerides) from baseline
時間枠:Baseline, 16 weeks
|
Lipid profile TG measured at initial and final visits |
Baseline, 16 weeks
|
|
Change in lipid profile small LDL (small dense LDL) from baseline
時間枠:Baseline, 16 weeks
|
Lipid profile small LDL measured at initial and final visits |
Baseline, 16 weeks
|
|
Change in lipid profile (HDL) from baseline
時間枠:Baseline,16 weeks
|
Lipid profile HDL measured at initial and final visits |
Baseline,16 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Psychiatric Indices - Mood
時間枠:Baseline, 16 weeks
|
Change in Mood Qualitative Score (Clinical Mood Monitoring) from baseline |
Baseline, 16 weeks
|
|
Psychiatric Indices- Clinical Global Impression
時間枠:Baseline, 16 weeks
|
Change in Clinical Global Impression Scales (CGI) from baseline 1-7 scale. 1= not at all ill, 7= among the most extremely ill patients) |
Baseline, 16 weeks
|
|
Generalized Anxiety Disorder - GAD-7 Anxiety
時間枠:Baseline, 16 weeks
|
Change in Generalized Anxiety Symptom (GAD-7) scale from baseline. 0-15+ scale. (0= no anxiety, 15+= severe anxiety) |
Baseline, 16 weeks
|
|
Patient Health Questionnaire - PHQ-9 Depression
時間枠:Baseline, 16 weeks
|
Change in Patient Health Questionnaire (PHQ-9) from baseline. Score range 0-27 (0= no depression, 27= severe depression) |
Baseline, 16 weeks
|
|
Psychiatric Indices- Global Assessment of Functioning
時間枠:Baseline, 16 weeks
|
Change in Global Assessment of Functioning (GAF) Scale from baseline. 1-100 scale (1= persistent danger of hurting self or others, 100= superior functioning) |
Baseline, 16 weeks
|
|
Psychiatric Indices- Quality of Life
時間枠:Baseline, 16 weeks
|
Change in Manchester Quality of Life Scale (MANSA) from baseline. Range 12-84 (each of 12 outcomes rated from 1= could not be worse to 7= could not be better; <4= dissatisfied with QoL, >4= satisfied with QoL) |
Baseline, 16 weeks
|
|
Psychiatric Indices- BPRS
時間枠:Baseline, 16 weeks
|
Change in Brief Psychiatric Rating Scale (BPRS) from baseline. Score range 18-126. (For each of 18 symptoms, 1=symptom not present, 7= extremely severe) |
Baseline, 16 weeks
|
|
Pittsburgh Sleep Quality Index - PSQI
時間枠:Baseline, 16 weeks
|
Change in Pittsburgh Sleep Quality Index from baseline. 0-21 scale (<5=good sleeper; 5+= meaningfully disturbed sleep or poor sleeper) |
Baseline, 16 weeks
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Shebani Sethi, MD、Stanford University
出版物と役立つリンク
一般刊行物
- Yu B, Ozveren R, Sethi Dalai S. Ketogenic diet as a metabolic therapy for bipolar disorder: Clinical developments. Submitted to Journal of Affective Disorders. Research Square preprint March 2020: DOI is: 10.21203/rs.3.rs-334453/v1
- Sarnyai Z, Kraeuter AK, Palmer CM. Ketogenic diet for schizophrenia: clinical implication. Curr Opin Psychiatry. 2019 Sep;32(5):394-401. doi: 10.1097/YCO.0000000000000535.
- Brietzke E, Mansur RB, Subramaniapillai M, Balanza-Martinez V, Vinberg M, Gonzalez-Pinto A, Rosenblat JD, Ho R, McIntyre RS. Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neurosci Biobehav Rev. 2018 Nov;94:11-16. doi: 10.1016/j.neubiorev.2018.07.020. Epub 2018 Jul 31.
- Norwitz NG, Sethi S, Palmer CM. Ketogenic diet as a metabolic treatment for mental illness. Curr Opin Endocrinol Diabetes Obes. 2020 Oct;27(5):269-274. doi: 10.1097/MED.0000000000000564.
- Sethi S, Sinha A, Gearhardt AN. Low carbohydrate ketogenic therapy as a metabolic treatment for binge eating and ultraprocessed food addiction. Curr Opin Endocrinol Diabetes Obes. 2020 Oct;27(5):275-282. doi: 10.1097/MED.0000000000000571.
- Sethi S, Wakeham D, Ketter T, Hooshmand F, Bjornstad J, Richards B, Westman E, Krauss RM, Saslow L. Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial. Psychiatry Res. 2024 May;335:115866. doi: 10.1016/j.psychres.2024.115866. Epub 2024 Mar 20.
- Carmen M, Safer DL, Saslow LR, Kalayjian T, Mason AE, Westman EC, Sethi S. Treating binge eating and food addiction symptoms with low-carbohydrate Ketogenic diets: a case series. J Eat Disord. 2020 Jan 29;8:2. doi: 10.1186/s40337-020-0278-7. eCollection 2020.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 48527
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。